RecruitingPhase 2NCT05800600
Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy
Sponsor
Fox Chase Cancer Center
Enrollment
34 participants
Start Date
Mar 15, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This is an open-label, single institution study evaluating the efficacy of intravenous iron sucrose monotherapy in patients with thoracic, breast, GU and GI malignancies undergoing neoadjuvant chemotherapy with the goal of undergoing surgical resection.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Male or female patients > 18 years
- Patients undergoing neoadjuvant chemotherapy, including radiation and/or immunotherapy, with intent for curative surgical resection for breast, thoracic, gastrointestinal (GI) or genitourinary (GU) malignancies.
- Anemia defined as Hgb <10.5 g/dL during chemotherapy.
- Iron storage levels of ferritin <500 ng/mL and iron saturation <35%
- Ability to understand and willingness to sign a written informed consent and HIPAA consent document
Exclusion Criteria7
- Diagnosis of anemia at the time of cycle 1 day 1 of neoadjuvant chemotherapy, Hgb < 11.0 g/dL, uncontrolled intercurrent illness including, but not limited to, ongoing active infection, symptomatic new/exacerbated congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Prior parenteral iron infusion in the past 4 weeks
- The use of erythropoietin stimulating agents within 4 weeks unless chronic needs due to CKD
- Concurrent systemic infection at the time of enrollment.
- Known hypersensitivity to Iron sucrose
- Pregnant or breast feeding. Refer to section 4.4 for further detail.
- Anemia from another established etiology (i.e MDS, Myeloma)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGVenofer
Intravenous iron will be administered as five doses of 200 mg of iron sucrose (Venofer, American Regent, Shirley, NJ) in 100 ml normal saline over a duration of 15 minutes to 1 hour
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05800600
Related Trials
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT07422480154 locations
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTX001 in Healthy Adults.
NCT075778171 location
Research Platform Myelofibrosis and Anemia
NCT069769181 location
The Effect of Combined Iron Protocols on Perioperative Allogeneic Transfusion
NCT060127601 location
The Effects of Intravenous Iron on Mobility in Elderly Patients Following Hip Fracture Surgery
NCT068988143 locations